A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sezary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study

Trial Profile

A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sezary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Resminostat (Primary)
  • Indications Mycosis fungoides; Sezary syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms RESMAIN
  • Sponsors 4SC
  • Most Recent Events

    • 03 May 2017 According to a 4SC media release, this study was presented at the 13th Congress of the European Association of Dermato-Oncology.
    • 16 Dec 2016 According to a 4SC media release, first patient has been enrolled. Company anticipates top-line data of this trial to be available in 2019 and intend to immediately submit the data to the relevant regulatory agencies for market approval in Europe.
    • 10 Nov 2016 According to a 4SC media release, this trial is on track to enrol first patient in Q4 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top